Cancer Research Cancer Health Disparities Conference 2009 SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lewis, K. A.
Right arrow Articles by Cliby, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lewis, K. A.
Right arrow Articles by Cliby, W. A.
[Cancer Research 65, 7091-7095, August 15, 2005]
© 2005 American Association for Cancer Research

Priority Reports

Heterozygous ATR Mutations in Mismatch Repair–Deficient Cancer Cells Have Functional Significance

Kriste A. Lewis1, Sally Mullany1, Bijoy Thomas1, Jeremy Chien2, Ralitsa Loewen1, Viji Shridhar2 and William A. Cliby1

Departments of 1 Obstetrics and Gynecology and 2 Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota

Requests for reprints: William A. Cliby, Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, 1317 Guggenheim, 200 1st Street, Southwest Rochester, MN 55905. Phone: 507-266-9323; Fax: 507-266-9300; E-mail: Cliby.william{at}mayo.edu.

ATR (ataxia telangiectasia and Rad3-related) function is necessary for the proper response to commonly used chemotherapeutic agents. Heterozygous truncating mutations in exon 10 of the ATR gene have been described in numerous cancers exhibiting microsatellite instability. We show that truncating mutations of ATR are capable of acting in a dominant-negative manner to abrogate ATR-dependent Chk1 phosphorylation and cell-cycle arrests after DNA damage. In addition, endometrial cell lines harboring ATR mutations are defective for ATR-dependent responses. These findings imply that ATR mutations play an important role in the development and clinical behavior of a subset of microsatellite instability–positive endometrial, colon, and stomach cancers.




This article has been cited by other articles:


Home page
 JCOHome page
D. Black, R. A. Soslow, D. A. Levine, C. Tornos, S. C. Chen, A. J. Hummer, F. Bogomolniy, N. Olvera, R. R. Barakat, and J. Boyd
Clinicopathologic Significance of Defective DNA Mismatch Repair in Endometrial Carcinoma
J. Clin. Oncol., April 10, 2006; 24(11): 1745 - 1753.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.